Company profile for CORNERSTONE THERAP

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cornerstone Therapeutics Inc. is now Chiesi USA, Inc. We are pleased to announce that a strong partnership which began in 2009 has resulted in the complete acquisition of Cornerstone Therapeutics Inc. by Chiesi Farmaceutici S.p.A. Along with a corporate name change to Chiesi USA, Inc. we are now a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. This transaction did not constitute a change of control for Cornerstone as C...
Cornerstone Therapeutics Inc. is now Chiesi USA, Inc. We are pleased to announce that a strong partnership which began in 2009 has resulted in the complete acquisition of Cornerstone Therapeutics Inc. by Chiesi Farmaceutici S.p.A. Along with a corporate name change to Chiesi USA, Inc. we are now a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. This transaction did not constitute a change of control for Cornerstone as Chiesi has owned a majority of Cornerstone’s outstanding shares since 2009. Effective March 13, 2014, Cornerstone Therapeutics Inc. changed its name to “Chiesi USA, Inc.” This name change is being instituted to reflect the Company’s new relationship with Chiesi. While our name is changing, our legal status, office address and contact details will remain the same. The company’s business remains fundamentally unaffected by this change and all contracts with existing customers will remain unaltered, with corresponding obligations and rights assumed under the new name. As Chiesi USA, our valued patients and providers will benefit from greater resources to support research and development initiatives, continued commitment to our key therapeutic areas, and continuity of operations in our Cary, NC headquarters. Though our ability to serve our customers’ needs has increased, there are no changes to our daily operations or contacts for our valued partners. We look forward to providing the same services that we have offered to our customers and partners to date. If you have any questions regarding the legal status of Chiesi USA, please contact Chiesi USA’s Legal Department at legal@crtx.com. About Chiesi USA, Inc. Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. About Chiesi Farmaceutici, Chiesi Farmaceutici is a research-focused international group with more than 75 years of experience and is headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the areas of respiratory and specialty therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Chiesi USA, Inc.
Telephone
Telephone
(888) 466-6505/6511
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

BePharma

Not Confirmed

envelop Contact Supplier

BePharma

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/06/16/2464300/28235/en/Cornerstone-Pharmaceuticals-Announces-Published-Data-on-CPI-613-Devimistat-as-an-Effective-Approach-to-Targeting-Carcinoma-Catabolism-UPDATE.html

GLOBENEWSWIRE
16 Jun 2022

https://www.globenewswire.com/news-release/2022/06/01/2454159/28235/en/Cornerstone-Pharmaceuticals-to-Present-Pancreatic-Cancer-Clear-Cell-Sarcoma-and-Biliary-Tract-Cancer-Research-Featuring-CPI-613-Devimistat-at-the-2022-American-Society-of-Clinical-.html

GLOBENEWSWIRE
01 Jun 2022

https://www.globenewswire.com/news-release/2022/05/24/2449592/28235/en/European-Medicines-Agency-Grants-Orphan-Drug-Designation-to-Cornerstone-Pharmaceuticals-CPI-613-Devimistat-for-Treatment-of-Patients-with-Advanced-Unresectable-Biliary-Tract-Cancer.html

GLOBENEWSWIRE
24 May 2022

https://globenewswire.com/news-release/2017/06/05/1008222/0/en/Cornerstone-Pharmaceuticals-Inc-Announces-Corporate-Name-Change-to-Rafael-Pharmaceuticals-Inc.html

GLOBENEWSWIRE
06 Jun 2017

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty